// App-Quantinova.ai

2047 : Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors

Researchers

Presenter

  • William C. Zamboni

Principal Investigators

  • Ben Markman

  • Paul de Souza

  • E. Claire Dees

  • Tara Gangadhar

  • Scott Eliasof

  • Curran Murphy

  • Adrian Senderowicz

  • Hongwei Wang

Medical Centers

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • Monash Medical Centre, Melbourne, Australia

  • Western Sydney University School of Medicine, Sydney, Australia

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Cerulean Pharma Inc., Cambridge, MA

Locations

  • United States

  • Australia

Companies

  • Cerulean Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Adk3 + Docetaxel

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved